Anti-VEGF treatment improves macular sensitivity in diffuse DME

ORLANDO, Fla. — Anti-VEGF treatment improved macular sensitivity in patients with diffuse diabetic macular edema but not in patients with focal diabetic macular edema, according to a poster presentation here.The study included 59 eyes of 45 patients with center-involving DME that were randomized into two groups: 33 eyes received 1.5 mg/0.06 mL intravitreal Avastin (bevacizumab, Genentech) and 26 eyes received 0.5 mg/0.05 mL intravitreal Lucentis (ranibizumab, Genentech).